POINT Biopharma Global Inc. is a radiopharmaceutical company that focuses on developing and commercializing radioligands to fight cancer. They have several product candidates in various stages of clinical trials, including PNT2002 and PNT2003, which are in Phase III trials for the treatment of prostate cancer and neuroendocrine tumors, respectively. POINT Biopharma Global Inc. was founded in 2019 and is headquartered in Indianapolis, Indiana.